EU orphan medicines regulation failed
July 29, 2020
Two decades of EU market protection of ‘orphan’ (rare disease) medicines have greatly benefitted the industry. According to research by The Investigative Desk, published in
Lucien Hordijk
Lucien Hordijk (1988) has been covering the pharmaceutical industry for six years, reporting on skyrocketing prices, regulatory capture, generic shortages, biosimilars and industry lobbying. His investigations led to national publications and international coverage in the Financial Times, The Wall Street Journal and Reuters.
Publications:
Evergreening the world’s most profitable medicine
March 27, 2019
Even after the expiration of Humira’s patent protection, AbbVie, the pharmaceutical company, almost completely fended off biosimilar competition for this blockbuster medicine in the Netherlands.
Reconstruction lutetium octreotate
January 9, 2019
By Lucien Hordijk Steve Jobs’ private plane, parked at Rotterdam Airport. It is September 2008 when local reporters receive tips about the arrival of Apple’s
